| pubmed-article:11967950 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11967950 | lifeskim:mentions | umls-concept:C0027651 | lld:lifeskim |
| pubmed-article:11967950 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:11967950 | lifeskim:mentions | umls-concept:C0618743 | lld:lifeskim |
| pubmed-article:11967950 | lifeskim:mentions | umls-concept:C0003250 | lld:lifeskim |
| pubmed-article:11967950 | lifeskim:mentions | umls-concept:C1333898 | lld:lifeskim |
| pubmed-article:11967950 | lifeskim:mentions | umls-concept:C0205369 | lld:lifeskim |
| pubmed-article:11967950 | lifeskim:mentions | umls-concept:C0079411 | lld:lifeskim |
| pubmed-article:11967950 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:11967950 | pubmed:dateCreated | 2002-5-23 | lld:pubmed |
| pubmed-article:11967950 | pubmed:abstractText | Human kallikrein 2 (hK2) and prostate-specific antigen (PSA) are serine proteases in the human kallikrein gene family that are 80% identical at the protein level. Like PSA, hK2 is expressed primarily in the prostate, making it an attractive bio-marker for prostate cancer development. In addition, its potent enzymatic activity may functionally affect the biology of prostate cancer. In order to further elucidate the possible roles of hK2 in prostate cancer, we have generated a panel of hK2-specific, non-PSA cross-reactive monoclonal antibodies. | lld:pubmed |
| pubmed-article:11967950 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11967950 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11967950 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11967950 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11967950 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11967950 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11967950 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11967950 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11967950 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11967950 | pubmed:month | May | lld:pubmed |
| pubmed-article:11967950 | pubmed:issn | 0270-4137 | lld:pubmed |
| pubmed-article:11967950 | pubmed:author | pubmed-author:MessingEdward... | lld:pubmed |
| pubmed-article:11967950 | pubmed:author | pubmed-author:TurnerMichael... | lld:pubmed |
| pubmed-article:11967950 | pubmed:author | pubmed-author:FisherTerrenc... | lld:pubmed |
| pubmed-article:11967950 | pubmed:author | pubmed-author:NoceraMaryAnn... | lld:pubmed |
| pubmed-article:11967950 | pubmed:author | pubmed-author:WillisRichard... | lld:pubmed |
| pubmed-article:11967950 | pubmed:author | pubmed-author:Abdul AlimC... | lld:pubmed |
| pubmed-article:11967950 | pubmed:author | pubmed-author:BrownDeborah... | lld:pubmed |
| pubmed-article:11967950 | pubmed:author | pubmed-author:BournePatrici... | lld:pubmed |
| pubmed-article:11967950 | pubmed:author | pubmed-author:di... | lld:pubmed |
| pubmed-article:11967950 | pubmed:author | pubmed-author:LordEdith MEM | lld:pubmed |
| pubmed-article:11967950 | pubmed:author | pubmed-author:FrelingerJohn... | lld:pubmed |
| pubmed-article:11967950 | pubmed:copyrightInfo | Copyright 2002 Wiley-Liss, Inc. | lld:pubmed |
| pubmed-article:11967950 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11967950 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:11967950 | pubmed:volume | 51 | lld:pubmed |
| pubmed-article:11967950 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11967950 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11967950 | pubmed:pagination | 153-65 | lld:pubmed |
| pubmed-article:11967950 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:11967950 | pubmed:meshHeading | pubmed-meshheading:11967950... | lld:pubmed |
| pubmed-article:11967950 | pubmed:meshHeading | pubmed-meshheading:11967950... | lld:pubmed |
| pubmed-article:11967950 | pubmed:meshHeading | pubmed-meshheading:11967950... | lld:pubmed |
| pubmed-article:11967950 | pubmed:meshHeading | pubmed-meshheading:11967950... | lld:pubmed |
| pubmed-article:11967950 | pubmed:meshHeading | pubmed-meshheading:11967950... | lld:pubmed |
| pubmed-article:11967950 | pubmed:meshHeading | pubmed-meshheading:11967950... | lld:pubmed |
| pubmed-article:11967950 | pubmed:meshHeading | pubmed-meshheading:11967950... | lld:pubmed |
| pubmed-article:11967950 | pubmed:meshHeading | pubmed-meshheading:11967950... | lld:pubmed |
| pubmed-article:11967950 | pubmed:meshHeading | pubmed-meshheading:11967950... | lld:pubmed |
| pubmed-article:11967950 | pubmed:meshHeading | pubmed-meshheading:11967950... | lld:pubmed |
| pubmed-article:11967950 | pubmed:meshHeading | pubmed-meshheading:11967950... | lld:pubmed |
| pubmed-article:11967950 | pubmed:meshHeading | pubmed-meshheading:11967950... | lld:pubmed |
| pubmed-article:11967950 | pubmed:meshHeading | pubmed-meshheading:11967950... | lld:pubmed |
| pubmed-article:11967950 | pubmed:meshHeading | pubmed-meshheading:11967950... | lld:pubmed |
| pubmed-article:11967950 | pubmed:meshHeading | pubmed-meshheading:11967950... | lld:pubmed |
| pubmed-article:11967950 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:11967950 | pubmed:articleTitle | Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors. | lld:pubmed |
| pubmed-article:11967950 | pubmed:affiliation | Department of Microbiology and Immunology, School of Medicine and Dentistry, University of Rochester Cancer Center, 575 Elmwood Avenue, Rochester, NY 14642, USA. | lld:pubmed |
| pubmed-article:11967950 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11967950 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
